Objective: To compare short-term application of nasal high-frequency oscillatory ventilation (nHFOV) with nasal continuous positive airway pressure (nCPAP).
four 1-h treatment periods was used, such that each infant received both treatments twice. The primary outcome was the mean transcutaneous partial pressure of CO 2 (TcCO 2 ) value during the 2-h cumulative period of nHFOV compared with the 2-h cumulative period of nCPAP.
Results: Significantly lower TcCO 2 values were observed during nHFOV compared with nCPAP: 47.5 ± 7.6 versus 49.9 ± 7.2 mmHg, respectively, P = 0.0007. A different TcCO 2 behavior was found according to the random sequence: in patients starting on nCPAP, TcCO 2 significantly decreased from 50.0 ± 8.0 to 46.6 ± 7.5 mmHg during nHFOV (P = 0.001). In patients starting on nHFOV, TcCO 2 slightly increased from 48.5 ± 7.8 to 49.9 ± 6.7 mmHg during nCPAP (P = 0.13).
Conclusions: nHFOV delivered through nasal prongs is more effective than nCPAP in improving the elimination of CO 2 . tracheal intubation and mechanical ventilation are associated with ventilator-induced lung injury (VILI) and airway inflammation, leading to bronchopulmonary dysplasia (BPD). The mechanisms of this injury involve alveolar over distension, the presence of shear forces, and the release of pro-inflammatory cytokines, 3 moreover prolonged duration of intubation and mechanical ventilation is associated with an increased risk of death or survival with neurologic impairment. 4 In an effort to reduce VILI and consequently BPD in premature infants, there has been a trend toward increased use of noninvasive forms of respiratory support: nasal continuous positive airway pressure (nCPAP), nasal intermittent positive-pressure ventilation (nIPPV), high-flow nasal cannula (HFNC), nasal high-frequency oscillatory ventilation (nHFOV). 1, 2, [5] [6] [7] [8] [9] In this sense, nCPAP is an alternative to intubation and a meta-analysis focused on the use of early nCPAP versus intubation and ventilation showed that nCPAP reduces the risk of BPD. 10 Nonetheless, use of nCPAP in the delivery room may fail in extremely low birth weight infants, with 34-83% of such infants requiring subsequent intubation. Furthermore, post-extubation support with nCPAP in these infants is associated with a 16-40% failure rate at 1 week. nHFOV.
An investigating physician was dedicated to record on a respiratory sheet continuously at 1-min intervals directly from the monitor TcCO 2 , transcutaneous partial pressure of O 2 (TcO 2 ), heart rate, respiratory rate, SpO 2 , FiO 2 , cer-rSO 2 , ren-rSO 2 , CPAP, and amplitude levels (in cm H 2 O) as displayed on the CNO screen, episodes of apnea, bradycardia, and significant desaturation. Respiratory frequency was measured by electrodes placed on the chest. In particular, the physician ensured the accuracy of the spontaneous respiratory rate measurements checking the correspondence between the numbers displayed on the monitor and patients' chest movements.
Pain and discomfort were assessed hourly by the nursing staff using the neonatal pain, agitation, and sedation scale. Chicago, IL). Paired two-tailed t tests were employed, and P values <0.05 were considered statistically significant.
| RESULTS
During the study period, 62 VLBW infants were screened; 30 of them were enrolled and were randomized to receive a starting treatment mode of either nCPAP or nHFOV (Table 1 and Figure 1 ).
All recruited newborns have completed the study because they have not developed any sign of intolerance. There were no episodes of apnea during the study period and no significant differences in Figure 2 ). Significantly lower TcCO 2 values during nHFOV period (48.1 ± 7.1 mmHg) with respect to nCPAP period (49.4 ± 7.0 mmHg, P = 0.002) were observed even without considering the four extreme outliers (ie, the subjects showing a difference ≥8 mmHg between the two treatment blocks).
A different TcCO 2 behavior was found according to the random sequence: in patients starting on nCPAP, TcCO 2 significantly decreased from 50.0 ± 8.0 mmHg to 46.6 ± 7.5 mmHg during nHFOV (P = 0.001). In patients starting on nHFOV, TcCO 2 slightly increased from 48.5 ± 7.8 mmHg to 49.9 ± 6.7 mmHg during nCPAP (P = 0.13) (Figure 3 ).
Other physiological and hemodynamic variables, including heart rate, respiratory rate, and blood pressure were similar among treatment groups, as well as FiO 2 and mean airway pressure as displayed on the ventilator screen ( 13 We did not observe differences in the spontaneous respiratory rate between the two treatment blocks. Since CO 2 elimination under nHFOV is also provided in the upper airway, found between nCPAP and nHFOV periods, as shown in Table 2 . We also found no effects of nHFOV on heart rate, blood pressure or oxygenation. There were no episodes or apnea during the study period and no significant differences in desaturation or bradycardia events between the two treatment groups. nHFOV. 18 In a recent randomized controlled study, nHFOV significantly reduced the need for invasive mechanical ventilation as compared with nCPAP in preterm infants with moderate-severe RDS after surfactant administration via INSURE method, although no data on pCO 2 behavior are reported. 19 Regarding the respiratory setting adopted in our experience, amplitude and frequency adjustments were not made during the study period. There are no standard parameters for nHFOV in vivo at the moment: in fact most of the studies report the use of nHFOV delivered by different machines for invasive HFOV. In our study we used CNO, a machine designed to deliver noninvasive respiratory support specifically. The CNO ventilator is limited in the maximum amplitude it can generate, which in turn limits the tidal volume delivered: we decided to use the maximum power of amplitude, that is, 10 in order to overcome the high resistance of the upper airways.
The mean corresponding ΔP value measured in our study was limited Interestingly, even though a significant decrease of TcCO 2 was observed during nHFOV with respect to nCPAP in all patients, a different behavior was found according to the random sequence: in the patients starting on nCPAP, TcCO 2 significantly decreased during nHFOV while in patients starting on nHFOV, TcCO 2 slightly increased during nCPAP. This time-dependent effect might be related to a "long-acting" effect of nHFOV on pCO 2 levels. Although we only considered the last 20 min of each 1-h period for the final analysis of the data (just to allow for equilibration), it is possible that the effect of lowering pCO 2 during 1 h of nHFOV is partly maintained also during the following 1 h of nCPAP.
Our study's strengths include a rigorous protocol. We exposed the subjects to a uniform intervention for a standardized period of time and all the data have been observed directly by an experienced neonatologist and manually recorded on a respiratory sheet. The 2-h exposure to nHFOV was well tolerated by all our patients without any adverse effects and was effective in reducing TcCO 2 . The results of this study demonstrate that nHFOV delivered through nasal prongs is more effective than nCPAP in improving CO 2 elimination in premature infants who still require noninvasive respiratory support, in a short period of time.
Major limitations of our study are its small sample size and its short study time. 
